文献速递白血病淋巴瘤

种系NBN基因变异与儿童B细胞急性淋巴细胞白血病易感性

Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children.
PubMed 文献 · Blood · 2024-01-01

通过对4325例儿童B细胞急性淋巴细胞白血病(B-ALL)患者进行测序,系统分析种系NBN变异频率,并与gnomAD非癌症对照比较,发现B-ALL中NBN致病变异显著富集(P=0.004,比值比1.8)。功能实验验证25个变异中14个为严重功能丧失,NBN变异携带者生存结局与野生型相似。

要点

  • 儿童B-ALL中种系NBN致病变异显著富集,比值比1.8(P=0.004)。
  • 25个独特致病变异中14个经功能实验证实为无功能或部分功能。
  • NBN变异携带者(均为杂合)生存结局与野生型相似。

核心结论

  • 种系NBN变异与儿童B-ALL易感性相关,杂合携带者可能安全接受B-ALL治疗。

研究设计与样本

  • 对4325例儿童B-ALL患者进行种系NBN基因测序,并与gnomAD非癌症对照(118479人中472人携带189个独特致病变异)比较频率。

主要发现

  • 在50例患者中鉴定出25个独特、推定致病的NBN编码变异。
  • 与gnomAD对照相比,儿童B-ALL中NBN变异显著过表达(P=0.004;比值比1.8)。
  • 多数B-ALL风险变异为错义变异,聚集于NBN N端结构域。
  • 两种功能实验验证25个变异中14个为严重功能丧失表型,归类为无功能或部分功能。
  • 种系NBN变异携带者(均为杂合基因型)生存结局与野生型状态者相似。

关键数值与推荐

  • 儿童B-ALL中NBN致病变异频率显著高于gnomAD非癌症对照(P=0.004;比值比1.8)。
  • 25个独特致病变异中14个经功能实验证实为无功能或部分功能。

临床怎么用

  • 作者认为杂合NBN变异携带者可能安全接受B-ALL治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biallelic mutation in the DNA-damage repair gene NBN is the genetic cause of Nijmegen breakage syndrome, which is associated with predisposition to lymphoid malignancies. Heterozygous carriers of germ line NBN variants may also be at risk for leukemia development, although this is much less characterized. By sequencing 4325 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), we systematically examined the frequency of germ line NBN variants and identified 25 unique, putatively damaging NBN coding variants in 50 patients. Compared with the frequency of NBN variants in gnomAD noncancer controls (189 unique, putatively damaging NBN coding variants in 472 of 118 479 individuals), we found significant overrepresentation in pediatric B-ALL (P = .004; odds ratio, 1.8). Most B-ALL-risk variants were missense and cluster within the NBN N-terminal domains. Using 2 functional assays, we verified 14 of 25 variants with severe loss-of-function phenotypes and thus classified these as nonfunctional or partially functional. Finally, we found that germ line NBN variant carriers, all of whom were identified as heterozygous genotypes, showed similar survival outcomes relative to those with wild type status. Taken together, our findings provide novel insights into the genetic predisposition to B-ALL, and the impact of NBN variants on protein function and suggest that heterozygous NBN variant carriers may safely receive B-ALL therapy. These trials were registered at www.clinicaltrials.gov as #NCT01225874, NCT00075725, NCT00103285, NCI-T93-0101D, and NCT00137111.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Escherich CS, Chen W, Li Y, et al. Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children. Blood. 2024. PMID: 38446568. doi:10.1182/blood.2023023336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。